Compare NOTE & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOTE | CTXR |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | 439 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 16.8M |
| IPO Year | N/A | 2010 |
| Metric | NOTE | CTXR |
|---|---|---|
| Price | $0.77 | $0.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $37.50 | $6.00 |
| AVG Volume (30 Days) | 313.6K | ★ 636.8K |
| Earning Date | 03-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.60 | $147.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.40 | $0.63 |
| 52 Week High | $5.59 | $2.38 |
| Indicator | NOTE | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 30.92 | 45.08 |
| Support Level | $0.56 | $0.70 |
| Resistance Level | $0.85 | $0.99 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 13.20 | 13.32 |
FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.